|
|
|
1
|
Wiestner A.
More ZAP for chronic lymphocytic leukemia (CLL).
Blood 105(5): 1839-40, 2005.
[Text Abstract on PubMed]
|
|
|
2
|
Grube M, Rezvani K, Wiestner A, Fujiwara H, Sconocchia G, Melenhorst JJ, Hensel N, Marti GE, Kwak LW, Wilson W, Barrett JA.
Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies.
Clin Cancer Res 10(3): 1047-56, 2004.
[Text Abstract on PubMed]
|
|
|
3
|
Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, Hamblin TJ, Staudt LM, Oscier DG.
ZAP-70 expression and prognosis in chronic lymphocytic leukaemia.
Lancet 363(9403): 105-11, 2004.
[Text Abstract on PubMed]
|
|
|
4
|
Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM.
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Blood 101(12): 4944-51, 2003.
[Text Abstract on PubMed]
|
|
|
5
|
Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM.
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.
Proc Natl Acad Sci U S A 100(17): 9991-6, 2003.
[Text Abstract on PubMed]
|
|
|
6
|
Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI, Weksler BB, Schechter GP.
Rituximab in the treatment of acquired factor VIII inhibitors.
Blood 100(9): 3426-8, 2002.
[Text Abstract on PubMed]
|
|
|
7
|
Wiestner A, Tichelli A, Gratwohl A.
Howell Jolly bodies and a history of home-made bread.
Br J Haematol 114(2): 247, 2001.
[Text Abstract on PubMed]
|
|
|
8
|
Wiestner A, Padosch SA, Ghilardi N, Cesar JM, Odriozola J, Shapiro A, Skoda RC.
Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia.
Br J Haematol 110(1): 104-9, 2000.
[Text Abstract on PubMed]
|
|
|
9
|
Ghilardi N, Wiestner A, Kikuchi M, Ohsaka A, Skoda RC.
Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene.
Br J Haematol 107(2): 310-6, 1999.
[Text Abstract on PubMed]
|
|
|
10
|
Ghilardi N, Wiestner A, Skoda RC.
Thrombopoietin production is inhibited by a translational mechanism.
Blood 92(11): 4023-30, 1998.
[Text Abstract on PubMed]
|
|
|
11
|
Harrison CN, Gale RE, Wiestner AC, Skoda RC, Linch DC.
The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia.
Br J Haematol 102(5): 1341-3, 1998.
[Text Abstract on PubMed]
|
|
|
12
|
Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC.
An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia.
Nat Genet 18(1): 49-52, 1998.
[Text Abstract on PubMed]
|
|
|
13
|
Ghilardi N, Ziegler S, Wiestner A, Stoffel R, Heim MH, Skoda RC.
Defective STAT signaling by the leptin receptor in diabetic mice.
Proc Natl Acad Sci U S A 93(13): 6231-5, 1996.
[Text Abstract on PubMed]
|
|
|
14
|
Stoffel R, Wiestner A, Skoda RC.
Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets.
Blood 87(2): 567-73, 1996.
[Text Abstract on PubMed]
|
|
|
15
|
Widmer AF, Wiestner A, Frei R, Zimmerli W.
Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections.
Antimicrob Agents Chemother 35(4): 741-6, 1991.
[Text Abstract on PubMed]
|
|
|
16
|
Smith M, Herrell S, Lusher M, Lako L, Simpson C, Wiestner A, Skoda R, Ireland M, Strachan T.
Genomic organisation of the human chordin gene and mutation screening of candidate Cornelia de Lange syndrome genes.
Hum Genet 105(1-2): 104-11,
[Text Abstract on PubMed]
|
|
|